Kleper de Almeida, MD
Infectious Disease · Atlantis, FLNPI 1285600825
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 26.1% of the total. 2025 is the largest year on record at $269, 3.8 times the $70 reported in 2019. That places this record below the midpoint for infectious disease clinicians in FL, where the typical reported total is $652.
Across 31 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$147
- Insmed, Inc.$90
- Merck$75
- Amgen$60
- Lilly USA, LLC$38
- Gilead$30
- plus $122 from 7 others
Across 2 payments — averaging $5350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$11K
What the payments were for
- Food & beverage$562100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 9 | $147 |
| Insmed, Inc. | 4 | $90 |
| Merck | 4 | $75 |
| Amgen | 3 | $60 |
| Lilly USA, LLC | 2 | $38 |
| Gilead | 2 | $30 |
| Novo Nordisk | 1 | $25 |
| Pfizer | 1 | $25 |
| GSK | 1 | $19 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $15 |
| GE HealthCare | 1 | $14 |
| Organogenesis Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$562 in reported general payments places this provider in the 45th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 70 | $82,402 |
| EliquisApixaban | 63 | $65,651 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $45,918 |
| FarxigaDapagliflozin Propanediol | 29 | $21,192 |
| XareltoRivaroxaban | 28 | $19,501 |
| JardianceEmpagliflozin | 16 | $17,893 |
| RybelsusSemaglutide | 13 | $16,216 |
| Repatha SyringeEvolocumab | 14 | $7,708 |
| PaxlovidNirmatrelvir/Ritonavir | 24 | $2,881 |
| Atorvastatin Calcium | 178 | $2,541 |
| Ezetimibe | 45 | $1,671 |
| Estradiol | 13 | $1,049 |
| Valsartan | 35 | $997 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 23 | $918 |
| Tamsulosin Hcl | 27 | $896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $38 | $82,40270 claims |
| PfizerEliquis, Paxlovid | $25 | $68,53287 claims |
| GileadBiktarvy | $30 | $45,91812 claims |
| Johnson & JohnsonXarelto | $12 | $19,50128 claims |
| Novo NordiskRybelsus | $25 | $16,21613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Atlantis
- Larry BushAtlantis$26K
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.